Win a Compatibility Study For Injectable Products 

Unither Pharmaceuticals Offers a Compatibility Study For Injectable Products 

Unither Pharmaceuticals will be present at the World Vaccine Congress 2026, taking place March 30 – April 2, 2026 in Washington, DC, where the company is introducing a new initiative aimed at identifying promising collaborations in vaccines and biologics. 

Through this action, Unither invites biotech and pharmaceutical companies developing innovative injectable therapies to apply for a free preliminary compatibility study with the Euroject® platform, Unither’s Blow-Fill-Seal (BFS) single-dose injection technology. The selected project will have the opportunity to evaluate the compatibility of its vaccine or biologic candidate with the Euroject® delivery system and explore a potential pilot fill-and-finish evaluation. 

Companies attending the congress are encouraged to visit Unither at Booth 522 to learn more about the program and discover the potential of the Euroject® platform. 

About Euroject® 

Euroject® is an innovative single-dose injection device using BFS technology. This prefilled format enables simple, safe and costeffective vaccine administration, reducing logistical complexity and supporting largescale immunization programs.
Our dedicated building in Amiens, equipped with five filling lines, can produce over one billion doses per year, making Euroject® a powerful solution for global vaccination needs. 

Explore everything on our brandnew website section dedicated to : EUROJECT® | BFS Injectable | Prefilled Syringe | Unither 

Looking forward to connect with you and exploring future collaboration opportunities !